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Purpose: This study evaluated the cost-effectiveness
of ﬁrst-line treatments of relapsing–remitting multiple
sclerosis (RRMS) (dimethyl fumarate [DMF] 240 mg
PO BID, teriﬂunomide 14 mg once daily, glatiramer
acetate 20 mg SC once daily, interferon [IFN]-β1a
44 mg TIW, IFN-β1b 250 mg EOD, and IFN-β1a 30 mg
IM QW) and best supportive care (BSC) in the health
care payer setting in Finland.
Methods: The primary outcome was the modeled
incremental cost-effectiveness ratio (ICER; €/quality-
adjusted life-year [QALY] gained, 3%/y discounting).
Markov cohort modeling with a 15-year time horizon
was employed. During each 1-year modeling cycle,
patients either maintained the Expanded Disability Status
Scale (EDSS) score or experienced progression, developed
secondary progressive MS (SPMS) or showed EDSS
progression in SPMS, experienced relapse with/without
hospitalization, experienced an adverse event (AE), or
died. Patients' characteristics, RRMS progression proba-
bilities, and standardized mortality ratios were derived
from a registry of patients with MS in Finland. A mixed-
treatment comparison (MTC) informed the treatment
effects. Finnish EuroQol Five-Dimensional Questionnaire,
Three-Level Version quality-of-life and direct-cost
estimates associated with EDSS scores, relapses, and
AEs were applied. Four approaches were used to assess
the outcomes: cost-effectiveness plane and efﬁciency
frontiers (relative value of efﬁcient treatments); cost-
effectiveness acceptability frontier, which demonstrated
optimal treatment to maximize net beneﬁt; Bayesian
treatment ranking (BTR); and an impact investment
assessment (IIA; a cost-beneﬁt assessment), which
increased the clinical interpretation and appeal of
modeled outcomes in terms of absolute beneﬁt gained
with ﬁxed drug-related budget. Robustness of results
was tested extensively with sensitivity analyses.March 2017Findings: Based on the modeled results, teriﬂuno-
mide was less costly, with greater QALYs, versus
glatiramer acetate and the IFNs. Teriﬂunomide had
the lowest ICER (24,081) versus BSC. DMF brought
marginally more QALYs (0.089) than did teriﬂuno-
mide, with greater costs over the 15 years. The ICER
for DMF versus teriﬂunomide was 75,431. Teriﬂuno-
mide had 450% cost-effectiveness probabilities with
a willingness-to-pay threshold of o€77,416/QALY
gained. According to BTR, teriﬂunomide was ﬁrst-best
among the disease-modifying therapies, with potential
willingness-to-pay thresholds of up to €68,000/QALY
gained. In the IIA, teriﬂunomide was associated with
the longest incremental quality-adjusted survival and
time without cane use. Generally, primary outcomes
results were robust, based on the sensitivity analyses.
The results were sensitive only to large changes in
analysis perspective or mixed-treatment comparison.
Implications: The results were sensitive only to
large changes in analysis perspective or MTC. Based
on the analyses, teriﬂunomide was cost-effective
versus BSC or DMF with the common threshold
values, was dominant versus other ﬁrst-line RRMS
treatments, and provided the greatest impact on
investment. Teriﬂunomide is potentially the most
cost-effective option among ﬁrst-line treatments of537
Clinical TherapeuticsRRMS in Finland. (Clin Ther. 2017;39:537–557)
& 2017 The Authors. Published by Elsevier HS
Journals, Inc.
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Multiple sclerosis (MS)—a chronic progressive, auto-
immune, inﬂammatory disease—affects 42 million
people worldwide. Approximately 89% of cases are
classiﬁed as relapsing–remitting MS (RRMS) at the
time of diagnosis.1 MS prevalence is particularly high
in the United Kingdom, the United States, Canada,
Germany, and Scandinavia.2,3 In Finland, MS preva-
lence varies regionally, from 100 to 200 per 100,000
inhabitants.4–7
In young adults with MS, prognosis is based on
an individual’s factors.1 The progression and
accumulating disability cause a signiﬁcant human
and economic burden8–15 and the need for support.16
The risk for death among Finnish patients with MS
is 2.8-fold compared with that in the general popula-
tion, being 3.4-fold in women and 2.2-fold in men as
early as 2 to 10 years after diagnosis.17 Relapse, MS
progression, and disability level (eg, higher Expanded
Disability Status Scale [EDSS] score18) are associated
with a higher risk for mortality,17,19,20 additional
costs,9–14 and quality of life (QoL) losses.9,10,12,14,21–24
MS treatment with disease-modifying therapies
(DMTs) is aimed at decreasing the inﬂammatory
activity leading to relapses, stopping or slowing
progression of residual disability, and, eventually,
delaying the progression to the secondary progressive
phase. However, long-term prognosis among treated
patients is largely unknown. Based on Finnish drug
reimbursement and sales data,25 commonly used ﬁrst-
line DMTs include injectable DMTs, namely glatir-
amer acetate (GA), interferon (IFN)-β1a IM, IFN-β1a
SC, and IFN-β1b SC.
Dimethyl fumarate (DMF) and teriﬂunomide are
new oral DMTs reimbursed as the ﬁrst-line treatment
of RRMS in Finland. The efﬁcacy and safety of
DMF 240 mg BID for established MS have been
studied in the Phase III CONFIRM (Comparator and
an Oral Fumarate in Relapsing-Remitting Multiple
Sclerosis)26,27 and DEFINE (Determination of the538Efﬁcacy and Safety of Oral Fumarate in Relapsing–
Remitting MS)28,29 trials (ClinicalTrials.gov identi-
ﬁers: NCT00451451 and NCT00420212, respec-
tively). The efﬁcacy and safety of teriﬂunomide 14
mg once daily for established MS have been demon-
strated in the Phase III TEMSO (Teriﬂunomide Multi-
ple Sclerosis Oral Teriﬂunomide for Relapsing
Multiple Sclerosis)30–33 and TOWER (Teriﬂunomide
Oral in People With Relapsing Multiple Sclerosis)34,35
trials (NCT00134563 and NCT00751881, respec-
tively), and in patients with a ﬁrst clinical episode
suggestive of MS in the TOPIC (Oral Teriﬂunomide
for Patients with a First Clinical Episode Suggestive
of Multiple Sclerosis)36 trial (NCT00622700).
Effectiveness of teriﬂunomide compared with
IFN-β1b SC has been demonstrated in the Phase III
TENERE (Teriﬂunomide and Rebif® in Patients
with Relapsing Multiple Sclerosis)37 trial
(NCT00883337).
We evaluated the cost-utility of injectable and oral
ﬁrst-line DMTs in the Finnish population of patients
with RRMS, based on a decision-analytical model. To
our knowledge, there are no previously published
journal articles on the cost-utility of ﬁrst-line oral
DMTs in a European setting or on oral and injectable
DMTs for ﬁrst-line treatment of RRMS. In addition,
progression of RRMS in Finnish patients has not been
assessed before, and the 4 different approaches elab-
orating the key results from MS cost-utility analysis
have not been previously reported.MATERIALS AND METHODS
The cost-utility of the ﬁrst-line DMTs in the Finnish
RRMS population was assessed in a decision-
analytical modeling framework38 by implementing
a Markov cohort model with mutually exclusive
health states in Excel 2007, including Visual
Basic for Applications (Microsoft Corporation,
Redmond, Washington). The modeling approach
followed the Finnish guidance for health economic
analyses.39
The primary outcome of analysis was the modeled
incremental cost-effectiveness ratio (ICER), reported
as Euros per quality-adjusted life-year (€/QALY)
gained. The interpretation of ICER is challenging in
Finland because the decision maker’s willingness-to-
pay (WTP) threshold per QALY gained has not been
publicly declared,40 and signiﬁcant variation inVolume 39 Number 3
E. Soini et al.decision maker WTP between diseases may exist.41
Based on our experience, the UK thresholds42,43
could be applicable in Finland, so that values of
o€25,000 or €25,000–37,000/QALY gained
would indicate most plausible or plausible cost-effec-
tiveness, respectively; and, on average, €55,000/
QALY gained could be acceptable for end-of-life
treatment based on the UK population-weighted
decisions. This applicability of UK thresholds is based
on the observation that many articles from Fin-
land41,44–55 have referred to a WTP threshold of
€50,000/QALY gained, which is probably based
on the so-called "dialysis argument."41 The Finnish
Medicines Agency has considered that €68,000/QALY
gained approaches the maximum cost-effectiveness
threshold for a life-threatening cancer56—a result
well in line with earlier Finnish average ﬁndings.41
The health care payer setting, which is recom-
mended in the Finnish guidance for health economic
analyses,39 was used in the modeling. This model
includes direct health and social care costs, and
excludes income transfers (taxes) and indirect costs
(eg, time costs, disability payments, presenteeism,
absenteeism, and informal care). A scenario analysis,
including productivity losses,14 was performed to
assess the robustness of this direct-costing perspective.
A summary of the modeled key research questions is
given in Table I as an extended PICO framework,
which is used to capture and clarify the essential parts
of complicated cost-effectiveness assessment in a
sensible order (namely, PICOSTEPS: P, patients; I,
interventions; C, comparator; O, outcomes; S, setting;
T, time horizon; E, effects; P, perspective; and S,
sensitivity analyses).
A relatively straightforward, limited cost–beneﬁt
analysis (clinical value analysis) approach was recently
developed.46 As a secondary complementary analysis,
an impact investment assessment (IIA) was carried out
to increase the clinical appeal and interpretation of the
primary outcome results.46 The IIA here covered a
ﬁxed drug-related budget based on the most afford-
able DMT and incremental quality-adjusted survival
or time to cane use (EDSS score, 6) versus best
supportive care (BSC; trial comparator). The outcome
(impact on investment [II]) of the IIA was the duration
of beneﬁt obtained in comparison with BSC with the
ﬁxed budget. This IIA incorporated an explicit mini-
mal willingness-to-invest (WTI) value for DMT based
on the most affordable DMT and, thus, demonstratedMarch 2017the mean absolute cost–beneﬁt in terms of a single
unit:
II¼ Drug health benefiti vs BSCð Þ
 Assumed drugrelated minimal WTIð Þ
Drugrelated costið Þ
(Equation 1)
where i indicates a particular drug treatment.
Consequently, the result of the IIA is a standardized
beneﬁt (II) obtained with the given WTI (in fact, the
WTI can be greater than the minimum assumed here,
and the beneﬁt increases accordingly).Patients
Finland’s MS research registry data were used to
deﬁne the cohort characteristics in the model. Based
on the MS research registry data (713 ambulatory
patients from Finland, with MS diagnosed in 1991–
2010 and an EDSS score of 0–6.5 observed at base-
line; see Supplemental Material A in the online version
at http://dx.doi.org/10.1016/j.clinthera.2017.01.028),
the mean age of modeled patients was 35.64 years,
and the female/male ratio was 2.57. The distribution
of EDSS scores at baseline is shown in Figure 1.Model
The clinical course of MS was modeled
(Figure 2)73,74 to capture all relevant evidence,38,39,43
as no direct comparison is currently available. Models
are always hypothetical and contain an element of
uncertainty, but when relying on conservative and fair
structure and estimates—and keeping the modeling
assumptions in mind—they can produce useful infor-
mation for decision making.
In the model shown in Figure 2, patients with
RRMS either maintained the same EDSS or transited
to another EDSS health state as the disease progressed,
developed secondary progressive MS (SPMS),
transited to another EDSS state in SPMS, or died
(EDSS score, 10; absorbing state) within the 1-year
model cycles. Within each cycle, patients experienced
a relapse (with/without hospitalization) and/or an
adverse event (AE). The relative effects of DMTs were
implemented as modiﬁers of the modeled clinical
course of MS. Midcycle estimates (life-table method
of half-cycle correction75–77) were used to avoid over-
or underestimation of modeled outcomes.539
Table I. PICOSTEPS: Summary of the research questions.
PICOSTEPS Description
P: Patients Finnish adults with incident RRMS and EDSS scores 0.0–6.5 at baseline based on data from
a Finnish MS registry
I: Interventions DMTs: DMF 240 mg PO BID, teriﬂunomide 14 mg once daily, GA 20 mg SC once daily, IFN-
β1a 44 mg SC TIW, IFN-β1b 250 mg SC EOD, IFN-β1a 30 mg IM QW
C: Comparator Common comparator: BSC (trial placebo)
O: Outcomes Primary: ICER given as the cost/QALY gained based on the direct cost
Secondary: disaggregated and total QALYs (based on EQ-5D-3L) and costs, life-years, years
without impaired mobility (EDSSo6; ie, years without cane use), cost-effectiveness plane
and efﬁciency frontiers, cost-effectiveness acceptability frontiers, Bayesian treatment
ranking, and cost–beneﬁt assessment. Discounting: 3%/y
S: Setting Probabilistic decision analytical modeling (Markov cohort model), including 21 health states
reﬂecting the disease progression (modiﬁed by treatment efﬁcacy); and events reﬂecting
relapses, AEs, and withdrawals
T: Time horizon 15 years, based on the follow-up data from the Finnish registry, time since diagnosis in a
Finnish cost and EQ-5D-3L MS study,14 years covered by the British Columbia, Canada,
registry,57,58 and approximate time from RRMS to SPMS in the London Ontario MS
registry database. For the London Ontario MS registry origins, see Weinshenker et al.59
E: Effects RRMS progression: Finnish MS registry data (see Supplemental Material A in the online
version at http://dx.doi.org/10.1016/j.clinthera.2017.01.028). SPMS progression: London
Ontario MS registry (see Supplemental Material A in the online version at http://dx.doi.
org/10.1016/j.clinthera.2017.01.028). Relapse rates: published elsewhere.21,60 Relapse-
associated hospitalizations: published elsewhere.30,32,33 Mortality: Finnish MS registry
data and statistics61 with EDSS-related17 adjustment. EDSS-associated costs and quality
of life: estimated from a Finnish study.14 Relapse costs: Finnish MS registry data. Relapse
disutility: Finnish study14 accounting for hospitalization status and duration.23,24
12-wk responses with DMT, annual relapse rates, and withdrawals: mixed-treatment
comparison.62,63 DMT effects on relapses resulting in hospitalizations: published
elsewhere.32,64,65 DMT costs: drugs,66 monitoring.67–71 AEs: disutility,72 duration, costs,
and occurrence (see Supplemental Material B in the online version at http://dx.doi.org/
10.1016/j.clinthera.2017.01.028).
P: Perspective Finnish payer perspective. A scenario analysis with a societal perspective.
S: Sensitivity
analyses
25 deterministic scenarios: impact of modeling assumptions, result robustness, and
generalizability
Probabilistic sensitivity analysis: joint uncertainty of the input estimates
AE ¼ adverse event; BSC ¼ best supportive care; DMF ¼ dimethyl fumarate; DMT ¼ disease-modifying therapy; EDSS ¼
Expanded Disability Status Scale; EQ-5D-3L ¼ EuroQol Five-Dimensional Questionnaire, Three-Level Version; GA ¼
glatiramer acetate; ICER ¼ incremental cost-effective ratio; IFN ¼ interferon; MS ¼ multiple sclerosis; QALY ¼ quality-
adjusted life-year; RRMS ¼ relapsing–remitting multiple sclerosis; SPMS ¼ secondary progressive multiple sclerosis.
Clinical TherapeuticsDisease Progression
Disease progression and relapses were modeled
independently. Disease progression in terms of the
EDSS score development during RRMS was estimated540from Finland’s MS research registry data, consisting
of 2299 EDSS measurements. The probability of
transiting from RRMS to SPMS was estimated, and
EDSS development during SPMS was based on resultsVolume 39 Number 3
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Figure 1. Expanded Disability Status Scale
(EDSS) score distribution at the in-
itiation of modeling.
E. Soini et al.from the London Ontario registry of MS (see
Supplemental Material A in the online version at http://
dx.doi.org/10.1016/j.clinthera.2017.01.028). For the
origins of registry, see Weinshenker et al.59 The relapse
rates in patients not receiving DMTs were taken from
published references.21,60 The percentage of relapses
leading to hospitalization (30.7%) was estimated from
the TEMSO trial.30,32,33
The annual probability of death was modeled
based on Finland’s general population mortality rates
by applying the observed MS female/male ratio of
2.57 from Finland’s MS research registry data totransitions may happen between EDSS 0-9 and to deathSPMS
Death
0 1 2 3 4 5 6 7 8 9
0 1 2 3 4 5 6 7 8 9
RRMS transitions may happen between EDSS 0-9, to SPMS and to death
Figure 2. Simplified presentation of the Markov
model and its key health states. Re-
lapses and adverse events are not
depicted. EDSS ¼ Expanded Disability
Status Scale; RRMS ¼ relapsing–remit-
ting multiple sclerosis; SPMS ¼ sec-
ondary-progressive multiple sclerosis.
March 2017Finland’s all-cause age- and sex-speciﬁc mortality
rates from the year 2014,61 multiplying the sex-
weighted general population mortality rate by the
EDSS-speciﬁc standardized mortality ratio, and con-
verting the result to give the probability.78 The EDSS-
speciﬁc standardized mortality ratio was estimated
from Finland’s MS research registry results17 by using
linear interpolation:
Standardized mortality ratio
¼0:515  EDSSþ1:000 (Equation 2)
Treatment Efficacy and Tolerability
Treatment efﬁcacy was assessed by common MS
study outcomes: sustaining the same disability status
for 12 weeks, annualized relapse rate (ARR), and
relapses. Persistence was assessed by withdrawal rates,
and tolerability, by AEs. Relative rates of hospital-
ization in the model were derived from the following
clinical trials: IFN-β1a SC, CARE MS I (Comparison
of Alemtuzumab and Rebif Efﬁcacy in Multiple
Sclerosis)64 (assumed to apply to GA and IFN-β1b
SC); IFN-β1a IM, TRANSFORMS (Trial Assessing
Injectable Interferon versus FTY720 Oral in
Relapsing–Remitting Multiple Sclerosis)65; and
teriﬂunomide, TEMSO32 (assumed to apply to
DMF). Withdrawals were assumed to happen at the
initiation of a new model cycle (but not at the start
of the ﬁrst cycle), and patients were assumed to
discontinue their current treatment when they
progressed from RRMS to SPMS.
Disability progression, ARR, and withdrawal rates
were modeled based on a mixed-treatment compar-
ison assessed by the National Institute for Health
and Care Excellence.62,63 To account for new MS
diagnostics, earlier treatment, and evidence of de-
creased ARR over time, the base case analysis
included trials that enrolled Z80% of patients who
had RRMS and had been recruiting patients since
2000. In addition, multiway sensitivity analyses
(disability progression, ARR, withdrawal rates) of
mixed-treatment comparison without year limit and
with or without adjustment for placebo relapses were
performed.
Treatment safety was modeled using reported AEs
from clinical trials or earlier health technology assess-
ments, their costs, and QoL effects (see Supplemental
Material B in the online version at http://dx.doi.org/
10.1016/j.clinthera.2017.01.028). AEs reported with541
Clinical Therapeuticssimilar terms were assumed to be treated similarly and
to result in similar QoL loss.Quality-adjusted Survival
The EuroQol Five-Dimensional Questionnaire,
Three-Level Version (EQ-5D-3L) QoL for EDSS
scores was modeled on the basis of data from
DEFENSE (Burden of Illness in Multiple Sclero-
sis),14 a recent cross-sectional survey from Finland.
The occurrence and impact72 of AEs (see
Supplemental Material B in the online version at
http://dx.doi.org/10.1016/j.clinthera.2017.01.028)
and relapses14,24 were accounted for. Finland’s
EDSS - re l a t ed QoL va lues 14 were deemed
acceptable because the mean EQ-5D-3L score in
EDSS 0-1 was in line with values from the general
population of Finland.79 However, the study from
Finland14 did not specify QoL related to relapse
with and without hospitalizations.
Findings from studies suggest greater disutility for
relapse with hospitalization compared with relapses
without hospitalization.23,24 In a US study, the QoL
losses in relapsed patients with and without hospital-
ization were reported as –0.302 and –0.091, respec-
tively.24 The latter estimate is similar to the Finnish
relapse loss, that is, –0.064,14 which used an extensive
1-year recall period and did not make a distinction
between hospitalized and nonhospitalized patients or
number of relapses.
To approximate the QoL loss associated with
hospitalizations, the Finnish QoL loss was weighted
with the observed ratio between the QoL losses for
hospitalized and nonhospitalized relapses in the US
study24 (ratio –0.302/–0.091 ¼ 3.3187) to obtain
disutility for hospitalized patients in Finland. The
applied QoL losses in relapsed patients with and
without hospitalization in the model were –0.212
and –0.064, respectively. The QoL effect of relapse
was assumed to last for 3 months.23Costs
Annual DMT cost was calculated using the indi-
cated mean dose of each drug and number of doses
per year (365.25 d/y), determined for each treatment
regimen based on the product labeling. For drugs with
multiple package sizes, the drug costs were estimated
by weighting of the package costs by their estimated542market share (Table II). A 100% dose intensity and
adherence were assumed.
Administration, monitoring (Table III), and AE
costs (see Supplemental Material B in the online
version at http://dx.doi.org/10.1016/j.clinthera.2017.
01.028) were calculated on the basis of resource
consumption multiplied by the associated unit costs.
DMT-associated resources were based on the product
labeling, recommendations in Finland,1,80,81 publica-
tions or earlier assessments (see Supplemental Material B
in the online version at http://dx.doi.org/10.1016/
j.clinthera.2017.01.028), and clinical practice.
In addition to the EQ-5D-3L QoL scores, which are
hard to predict with common regressions,82,83 the
DEFENSE survey14 assessed the costs of patients with
MS in Finland. The EDSS-related direct costs were
estimated based on data from the DEFENSE survey14
and are reported in Table III. Because of limitations in
the assessment of DEFENSE-derived relapse costs, the
costs of relapses were estimated from other patients
with RRMS in Finland (Tampere; N ¼ 581; data
included procedures, hospital visits, hospital stays,
and unit cost70) using semilog multivariate
methodology explained elsewhere.47,84 Based on this
analysis, the additional costs per relapse with and
without hospitalization were €5537.57 and €1297.41,
respectively.
In a scenario analysis, the relationship between
EDSS and annual direct care costs (excluding DMT
costs) was estimated based on a nonlinear interpola-
tion of ﬁndings reported in a study from Finland,13 as
follows:
Annual direct ðDMTs excl:Þ costs
¼€ð128:44  EDSS2þ4266:60  EDSS–2480:10Þ;
(Equation3)
converted to 2014 real value71 and with EDSS 0 set to
€0. The costs applied in this sensitivity analysis were
well in line with those from other MS cost studies
from Finland15 and elsewhere.9–11
Apart from the drugs, which were valued at
January 2016 prices,66 health care costs were valued
at 2013–2014 real prices. The required inﬂation
adjustments were performed using Finland’s ofﬁcial
price index for communal health care expenditures or
income index.71,85 The modeled costs and health
outcomes were discounted at 3%/y.Volume 39 Number 3
Table II. Drug-related use and costs.
DMT Dose/Amount per Package
Cost per
Package,€* Dosage (SPCs) Use, % Cost, €
DMF 120 mg† 120 mg, 14 tablets 188.37 120 mg PO BID 1.92 14,435/1st y
DMF 240 mg† 240 mg, 56 tablets 1151.56 240 mg PO BID 15.33
240 mg, 168 tablets 3319.33 82.75
DMF 240 mg† 240 mg, 56 tablets 1151.56 240 mg PO BID 15.33 14,523/2nd y
240 mg, 168 tablets 3319.33 84.67
GA 20 mg‡ 20 mg/mL, 28  1 mL 836.11 20 mg SC once daily 100.00 10,907
IFN-β1a 30 mg IM§ 30 mg/0.5 mL, 4  0.5 mL 814.90 30 mg SC QW 100.00 10,630
IFN-β1a 44 mg SC‖ 44 mg/0.5 mL, 12  0.5 mL 897.83 44 mg SC TIW 100.00 11,712
IFN-β1b 250 mg SC¶ 250 mg/mL, 15  1 mL 793.08 250 mg SC EOD 100.00 9656
Teriﬂunomide 14 mg# 14 mg, 28 tablets 1017.89 14 mg PO once daily 15.33 12,023
14 mg, 84 tablets 2712.79 84.67
DMT ¼ disease-modifying therapy; DMF ¼ dimethyl fumarate; GA ¼ glatiramer acetate; IFN ¼ interferon; SPC ¼ summary
of product characteristics.
*Drug costs are at January 2016 values.
†Trademark: Tecﬁderas (Biogen, Weston, Massachusetts).
‡Trademark: Copaxones (Teva, Ulm, Germany).
§Trademark: Avonexs (Biogen).
‖Trademark: Rebifs (EMD Serono, Rockland, Massachusetts).
¶Trademark: Betaferons (Bayer Pharmaceuticals, West Haven, Connecticut).
#Trademark: Aubagios (Genzyme [a Sanoﬁ Company], Cambridge, Massachusetts).
E. Soini et al.Sensitivity and Generalizability of Results
The robustness and generalizability of the base case
results were assessed using various deterministic and
probabilistic sensitivity analyses (DSA and PSA, re-
spectively). The base case was based on most credible
inputs. DSAs were based on 25 different scenarios,
including major or noncredible changes in methods,
health risks, treatment, costs, QoL, population, and
settings. Means based on all 25 DSA scenarios were
also calculated. The details of the DSAs are shown in
Table IV.Probabilistic Sensitivity Analysis
For PSA, a second-order Monte Carlo simulation
was used to take into account the joint variation in the
economic and clinical outcomes due to sampling
uncertainty related to model parameters. The follow-
ing distributions were used: β for ARR and with-
drawal rates, γ for EDSS-related and treatment costs,
log-normal for EDSS transitions, disease progression
hazard rates, treatment effect on ARR, treatmentMarch 2017effect on hospitalization relapse percentage and
QoL, and Dirichlet distribution for the percentage of
relapses involving hospitalization (see Supplemental
Material C in the online version at http://dx.doi.org/
10.1016/j.clinthera.2017.01.028). Based on the PSA,
cost-effectiveness acceptability frontiers demonstrated
optimal treatment to maximize net beneﬁt with differ-
ent WTP thresholds, and Bayesian treatment ranking
ranked the best treatments.RESULTS
The average modeled base case results are reported in
Table V. The mean projected 15-year total payer’s
direct costs differed considerably (by 17.2%) between
the most affordable (teriﬂunomide) and the most
costly (IFN-β1b SC) DMT. The respective relative
QALY gain difference was 9.3%. The maximum
relative QALY difference was 10.6% between the 2
DMTs (DMF and IFN-β1b SC).
The modeled key outcome (ICERs €/QALY gained in
comparison with BSC alone) ranged considerably, from543
Table III. Monitoring and disability (EDSS)-related resource use and costs.
Monitoring Unit Cost, €*
Resources, First Year/Later Year†
DMF GA IFNs Teriﬂunomide BSC
Specialist visit 340.76, Including 5%
copayment69
2/1 2/1 2/1 2/1 0/0
SC training 50.97 Nurse visit69 0/0 1/0 1/0 0/0 0/0
Laboratory fee‡ 5.4768 4/4 0/0 4/1 17/6 0/0
ALT 1.0067 4/1 0/0 4/1 17/6 0/0
GGT, creatinine 2.0067 4/1 0/0 0/0 0/0 0/0
BC 1.5567 0/0 0/0 4/1 0/0 0/0
FBC 6.6067 4/4 0/0 0/0 4/1 0/0
MxA 92.5070 0/0 0/0 1/1 0/0 0/0
TSH 2.5067 0/0 0/0 1/0 0/0 0/0
UT 5.8468 4/1 0/0 0/0 0/0 0/0
MRI, head 335.5869 1/0.5 1/0.5 1/0.5 1/0.5 0/0
Phone call§ 9.56 After tests69 2/3 0/0 2/0 15/5 0/0
Disability related
EDSS score14 – 0/1 2/3 4/5 6/7 8–9
Direct health
care costs, €‖
– 1108/1446 2890/3470 3909/5656 7919/12,185 15,718
Direct non–health
care costs, €
– 49/834 1693/4526 5767/15,289 18,749/32,364 68,852
ALT ¼ alanine aminotransferase; BC ¼ blood count; BSC ¼ best supportive care; DMF ¼ dimethyl fumarate; EDSS ¼
Expanded Disability Status Scale; FBC ¼ full blood count; GA ¼ glatiramer acetate; GGT ¼ gamma-glutamyl transferase;
MRI ¼ magnetic resonance imaging; MxA ¼ protein induced by interferon-alfa/β; TSH ¼ thyroid-stimulating hormone; UT
¼ urine test.
*Pre-2013 nontariff costs14,68,69 were indexed to the 2014 price level using ofﬁcial communal price index for health care
services.71
†Unless otherwise noted.
‡Fixed laboratory fee for each test taking time.
§Phone call after laboratory tests if specialist visit not arranged.
‖Estimated costs of disease-modifying therapies (DMTs) were excluded based on the digitalization and estimation of DMT
costs in Figure 4 in Ruutiainen et al.14
Clinical Therapeutics24,081 (teriﬂunomide) to 248,652 (GA) per QALY
gained, and BSC dominated IFN-β1b SC in the base
case. Teriﬂunomide was estimated to be less costly and
more effective (dominant) than injectable ﬁrst-line
DMTs, and DMF had a high ICER of 75,431 versus
teriﬂunomide, resulting from the marginally more QA-
LYs (0.089) with DMF and higher costs versus teri-
ﬂunomide over 15 years. (Table V and Figure 3).
If the WTP threshold for additional QALY gained
is set to the most plausible level (€25,000), only
teriﬂunomide represents a cost-effective alternative to544BSC alone, based on the modeling. If the WTP is
between €37,000 (plausible) and €55,000 (end of life)
per QALY gained, only teriﬂunomide and DMF
represent cost-effective alternatives to BSC alone.
However, with a modeled ICER of 75,414 for DMF
versus teriﬂunomide, DMF is unlikely to be consid-
ered cost-effective in the Finnish setting given the
unofﬁcial assumed WTP thresholds detailed in Mate-
rials and Methods.
The cost–beneﬁt analysis type IIA utilized the
minimal mean expected DMT-related discountedVolume 39 Number 3
Table IV. Details of deterministic sensitivity analyses.
Category Scenario
Discounting No discounting
Discounting with 5%/y
Health risks British Columbia, Canada, RRMS EDSS development, based on patients more than 28 years
old57
Alternative natural relapse source86
Rate for relapses leading to hospitalization based on the 1:2.75 ratio from Tampere data
(26.7% of annual relapses result in hospitalization when adjusting for covariates including
also EDSS score; N ¼ 581; mean age at relapse, 40 y)
Relapse time, 2 mo
Relapse time, 4 mo
Treatment DMT discontinuation when EDSS 7 and over was reached, based on reimbursement criteria
Disability progression and ARR set to the lower 95% credibility interval threshold of MTC
results
Disability progression and ARR set to the higher 95% credibility interval threshold of MTC
results
Alternative source disability progression, ARR, and withdrawal rates from the MTC: no year
limit and adjustment for placebo relapses
Alternative source disability progression, ARR, and withdrawal rates from the MTC: no year
limit
Time with AEs doubled (same as doubling AE disutility for those AEs that last a shorter time
than the model cycle)
Time with AEs halved (same as halving AE disutility)
Costs EDSS costs based on the other Finnish source13 at 2014 values61
Monitoring costs doubled
Monitoring costs halved
Relapse cost doubled
Relapse cost halved
AE costs doubled
AE costs halved
Societal approach (productivity loss included)14,85
QoL Alternative EDSS QoL source10
Similar QoL loss assumed for all relapses14
Result
generalizability
TEMSO30,32,33 patient characteristics and placebo transition probabilities for RRMS EDSS
AE = adverse event; ARR = annualized relapse rate; EDSS = Expanded Disability Status Scale; MTC = mixed-treatment
comparison; QoL = quality of life; RRMS = relapsing–remitting multiple sclerosis; TEMSO = Randomized Trial of Oral
Teriﬂunomide for Relapsing Multiple Sclerosis) Oral Teriﬂunomide for Patients with Relapsing Multiple.
E. Soini et al.budget per patient (minimum WTI) of €42,077 based
on the drug-related costs of IFN-β1a SC. The con-
sequent discounted IIs in terms of incremental
quality-adjusted survivals versus BSC were:March 2017teriﬂunomide, 0.337 QALYs gained; DMF, 0.314;
IFN-β1a SC, 0.264; GA, 0.120; IFN-β1a IM, 0.119;
and IFN-β1b SC, –0.239, all with the assumed WTI.
The respective incremental time to cane uses were545
Table V. Base case results (3%/y discounting).
Outcome DMF Teriﬂunomide
IFN-β1a
SC GA
IFN-β1a
IM BSC
IFN-β1b
SC
Primary
ICER vs BSC, €/QALY gained 33,681 24,081 57,690 248,652 244,105 – Dom.
ICER vs teriﬂunomide, €/QALY
gained
75,431 – Dom. Dom. Dom. 24,081 Dom.
Secondary
ICER vs BSC, €/y without
cane gained
24,692 17,371 43,881 236,722 174,995 – Dom.
ICER vs teriﬂunomide, €/y
without cane gained
59,512 – Dom. Dom. Dom. 17,371 Dom.
Total costs/patient, € 344,480 337,749 343,619 364,279 358,808 328,403 403,765
Total disease costs 280,427 289,275 301,543 313,535 314,881 328,403 356,527
Direct disability 67,630 69,047 71,430 73,851 73,577 75,721 81,726
Relapses 14,170 15,432 14,854 13,673 16,519 18,290 13,098
Other direct 198,626 204,796 215,258 226,011 224,784 234,392 261,703
Total treatment costs 64,053 48,474 42,077 50,744 43,927 0 47,237
Acquisition, administration 60,932 45,548 39,015 46,916 40,741 0 43,023
Monitoring 2976 2906 2518 2653 2833 0 3226
AEs 145 21 544 1175 353 0 989
Total QALYs/patient 7.808 7.719 7.595 7.475 7.456 7.331 7.063
Total disease QALYs 7.811 7.720 7.596 7.476 7.464 7.331 7.064
Disability QALYs 7.962 7.884 7.755 7.624 7.638 7.524 7.206
QALY loss due to relapses 0.151 0.164 0.159 0.147 0.175 0.193 0.142
QALY loss due to AEs 0.003 0.001 0.001 0.001 0.008 0.000 0.001
Total life-years 12.098 12.096 12.092 12.087 12.088 12.084 12.074
Years without cane
(EDSS o6)
8.393 8.280 8.089 7.894 7.916 7.742 7.252
AEs, adverse events; BSC = best supportive care; DMF = dimethyl fumarate; Dom. = dominated; GA = glatiramer acetate;
ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; IFN = interferon; QALY = quality-adjusted
life-year.
Clinical Therapeutics0.467, 0.428, 0.347, 0.126, 0.166, and –0.436 years,
respectively. Consequently, teriﬂunomide was pro-
jected to result in the highest II with the assumed WTI.
The results of 1-way and multiway sensitivity and
subgroup analyses (Table VI) show that the ranking
of DMTs in terms of incremental cost-effectiveness
appears to be generally robust for sensible changes in
modeling assumptions or input variables. The results
were sensitive to large changes in the modeled per-
spective or mixed treatment comparison. As the base
case was performed on the basis of a representative
population in Finland with characteristics well in line546with the indication for teriﬂunomide, TEMSO trial
results on patients’ characteristics and transition
probabilities in the placebo group were used in the
subgroup analysis. Based on the analysis, the results
are also generalizable to an older and more disabled
population. Among the 25 modeled DSA scenarios,
teriﬂunomide versus BSC was cost-effective in 72%,
84%, 96%, and 96% of scenarios with WTPs of
€25,000, €37,000, €55,000, and €68,000/QALY
gained, respectively. DMF versus teriﬂunomide was
cost-effective in 0%, 0%, 4%, and 28% of the 25
DSA scenarios at these respective WTPs.Volume 39 Number 3
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Figure 3. Cost-effectiveness plane and cost-ef-
fectiveness efficiency frontiers. BSC ¼
best supportive care; DMF ¼ dimethyl
fumarate; GA ¼ glatiramer acetate;
ICER ¼ incremental cost-effectiveness
ratio; IFN ¼ interferon; QALY ¼ qual-
ity-adjusted life-year.
E. Soini et al.For the results of the modeled PSA, see
Supplemental Material C in the online version at
http://dx.doi.org/10.1016/j.clinthera.2017.01.028. In
summary, the PSA results were in line with the
deterministic results—teriﬂunomide dominated
injectable ﬁrst-line DMTs, and DMF had a high mean
ICER of 76,803 (2.5%–97.5% percentile, 52,105–
139,595; 96% and 75% of ICERs exceeded 55,000
and 68,000, respectively) versus teriﬂunomide. Teri-
ﬂunomide had 450% cost-effectiveness probabilities
at WTPs of o€77,416/QALY gained versus other
ﬁrst-line DMTs. According to the Bayesian treatment
ranking, teriﬂunomide was the ﬁrst-best among the
DMTs with all unofﬁcial WTP thresholds from Fin-
land mentioned earlier.DISCUSSION
The ﬁndings from this modeling study of ﬁrst-line
DMTs for RRMS over 15 years suggest that teriﬂu-
nomide 14 mg saves costs in comparison with all
other reimbursed ﬁrst-line DMTs in Finland; is cost-
effective in comparison with DMF 240 mg at the cited
threshold values; dominates injectable ﬁrst-line
DMTs; and, as a complementary result, is associated
with the most value gained versus BSC as per theMarch 2017limited DMT-related budget (WTI). In some earlier
cost-utility analyses of ﬁrst-line DMTs for RRMS,87–91
DMTs in comparison with BSC have been found not to
be cost-effective based on the commonly cited threshold
values—the situation was similar with GA, IFN-β1a IM,
and IFN-β1b SC. These outcomes were largely explained
by drug prices and clinical parts of the analysis, that is,
short-term efﬁcacy and tolerability and long-term efﬁcacy
and persistence of treatments.
The ﬁndings from the cost–beneﬁt analysis type IIA
based on the WTI seemed to follow the primary
outcomes, yet a clear distinction on modeled II for
teriﬂunomide versus BSC in comparison with other
DMTs versus BSC was demonstrated with the assumed
minimal DMT-related WTI of €42,077/patient. The
IIA developed recently is a clinical value-assessment
method that could increase clinical interpretation and
appeal of the results, and indicate best IIs. However,
based on the ﬁndings from Soini et al,46 IIA cannot
fully substitute the primary cost-effectiveness analysis
outcomes if it ignores everything other than drug costs,
differences in QoL, differences in AEs, and discounts
and mixes the time horizons (ie, costs and beneﬁts are
gained from different timelines). Thus, IIA can easily
result in investment biases and partial optimization of
limited budgets. IIA, as such, probably should not be
used as a primary method without acknowledging its
limitations—here, the objective of the IIA was only to
elaborate and complement the primary outcome based
on a clear DMT-related cost and DMT-related II
approach. In this study, the IIA was based on a
modeling approach capable of synthesizing all of the
known evidence. Comprehensive methods and data
were needed for a valid IIA.
In addition to modeling methods, data validity and
generalizability can be an issue in decision-analytical
modeling. For example, the DEFENSE survey14 is the
most comprehensive, recent, and up-to-date assess-
ment of the MS burden in Finland. However, the
results from DEFENSE, as such, should be interpreted
with caution. There are various reasons for this: the
DEFENSE setting was cross-sectional, with varying
patient recall (ie, recall bias can be an issue and there
was no link between the cost outcomes and varying
recall time, eg, relapses and EDSS-related costs); the
base population was limited to active Finnish Neuro
Society members, with only 36.9% of invited mem-
bers participating in the survey (ie, about 10% of the
Finnish Neuro Society); EDSS was self-assessed547
Table VI. Scenario analysis results.
Parameter
DMF Teriﬂunomide IFN-β1a SC GA IFN-β1a IM BSC
IFN-β1b
SC ICER vs BSC, €/Q gained ICER, €/Q gained
t€ Qs t€ Qs t€ Qs t€ Qs t€ Qs t€ Qs t€ Qs DMF Teriﬂunomide IFN-β1a SC IFN-β1a IM IFN-β1b SC DMF vs Teriﬂunomide
Treatment scenario*
0 344 7.81 338 7.72 344 7.59 364 7.48 359 7.46 328 7.33 404 7.06 33,681 24,081 57,690 244,105 D2 75,431
1 435 9.31 428 9.19 437 9.03 462 8.88 456 8.86 424 8.71 513 8.36 17,117 7690 37,189 200,655 D2 57,611
2 299 7.02 292 6.95 297 6.84 315 6.74 310 6.72 280 6.61 348 6.38 45,200 35,488 71,757 274,356 D2 87,775
3 334 7.83 327 7.75 331 7.65 350 7.55 345 7.52 312 7.41 384 7.19 54,341 43,651 81,243 300,582 D2 100,644
4 352 7.73 346 7.64 351 7.51 372 7.39 367 7.37 338 7.23 412 6.98 28,834 19,963 50,325 226,293 D2 66,678
5 344 7.82 337 7.73 343 7.60 364 7.48 358 7.46 327 7.34 403 7.07 34,577 24,891 59,531 247,709 D2 76,741
6 344 7.86 338 7.77 344 7.65 364 7.52 359 7.51 328 7.40 404 7.11 34,692 24,677 60,243 256,395 D2 79,476
7 344 7.76 338 7.66 344 7.54 364 7.43 359 7.40 328 7.27 404 7.02 32,728 23,514 55,345 232,940 D2 71,778
8 343 7.80 337 7.71 343 7.59 362 7.47 357 7.45 328 7.33 399 7.71 31,961 22,404 55,085 235,817 186,098 73,618
9 323 8.06 317 7.96 314 7.93 318 8.00 322 7.87 328 7.33 325 7.93 D1 D1 D1 D1 D1 67,342
10 375 7.46 362 7.45 389 7.12 429 6.79 408 6.95 328 7.33 513 5.97 366,514 280,158 D2 D2 D2 1,784,824
11 333 7.93 327 7.84 341 7.64 348 7.84 355 7.51 328 7.33 378 7.32 8303 D1 41,383 152,493 D2 62,213
12 344 7.80 335 7.74 335 7.67 342 7.69 353 7.50 328 7.33 357 7.50 33,504 17,031 19,928 146,428 165,735 160,740
13 344 7.81 338 7.72 344 7.59 364 7.48 359 7.49 328 7.33 404 7.06 33,867 24,128 57,848 261,165 D2 77,031
14 344 7.81 338 7.72 344 7.59 364 7.48 359 7.46 328 7.33 404 7.06 33,586 24,057 57,610 236,352 D2 74,624
15 359 7.81 351 7.72 355 7.59 374 7.48 369 7.46 336 7.33 405 7.06 47,405 38,500 72,137 260,027 D2 86,131
16 347 7.81 341 7.72 346 7.59 367 7.48 362 7.46 328 7.33 407 7.06 39,916 31,568 67,235 266,852 D2 76,220
17 343 7.81 336 7.72 342 7.59 367 7.48 357 7.46 328 7.33 402 7.06 30,564 20,338 52,918 232,732 D2 75,036
18 359 7.81 353 7.72 358 7.59 378 7.48 375 7.46 347 7.33 417 7.06 25,050 16,717 44,662 229,887 D2 61,288
19 337 7.81 330 7.72 336 7.59 357 7.48 351 7.46 319 7.33 397 7.06 37,997 27,763 64,204 251,214 D2 82,502
20 345 7.81 338 7.72 344 7.59 365 7.48 359 7.46 328 7.33 405 7.06 33,985 24,135 59,752 246,942 D2 76,825
21 344 7.81 338 7.72 343 7.59 364 7.48 359 7.46 328 7.33 403 7.06 33,529 24,054 56,660 242,687 D2 74,734
22 563 7.81 559 7.72 569 7.59 594 7.48 588 7.46 561 7.33 646 7.06 3760 D1 30,202 215,755 D2 45,370
23 344 6.19 338 6.08 344 5.92 364 5.76 359 5.74 328 5.58 404 5.21 26,393 18,796 45,500 189,710 D2 60,137
24 344 7.87 338 7.78 344 7.65 364 7.53 359 7.53 328 7.41 404 7.11 35,308 25,205 62,785 264,278 D2 79,614
25 335 7.58 328 7.50 332 7.41 350 7.31 345 7.29 315 7.19 383 6.98 52,617 41,397 79,775 304,327 D2 101,341
Mean 355 7.76 348 7.68 355 7.55 374 7.45 370 7.41 339 7.28 413 7.06 33,147 22,608 58,452 244,916 D2 81,704
Δ0 þ10.8 –0.04 þ10.6 –0.04 þ11.2 –0.05 þ10.1 –0.03 þ11.1 –0.05 þ11.0 –0.05 þ9.1 0.00 –535 –1473 þ762 þ810 –43,928 þ6273
Δ0 ¼ difference vs base case; BSC ¼ best supportive care; D1 ¼ treatment dominates comparator; D2 ¼ comparator dominates treatment; DMF ¼ dimethyl
fumarate; GA ¼ glatiramer acetate; IFN ¼ interferon; ICER ¼ incremental cost-effectiveness ratio; Q ¼ quality-adjusted life-year; QoL ¼; t€ ¼ cost in thousand Euros.
*Scenarios: 0 ¼ base case; 1 ¼ 0% discounting; 2 ¼ 5% discounting; 3 ¼ British Columbia relapsing–remitting multiple sclerosis (RRMS) Expanded Disability Status
Scale (EDSS) transitions57; 4 ¼ relapses from Held et al86; 5 ¼ percentage of hospital relapses from Tampere; 6 ¼ relapse duration 2 mo; 7 ¼ relapse duration 4 mo;
8 ¼ EDSS 7 stopping rule for disease-modifying therapies; 9 ¼ mixed-treatment comparison (MTC): progression and annualized relapse rate (ARR) with low 95%
credible interval (CrI); 10 ¼ MTC: progression and ARR with high 95% CrI; 11 ¼ MTC: no year limit, relapses adjusted; 12 ¼ MTC: no year limit; 13 ¼ time with
adverse events (AEs) doubled; 14 ¼ time with AEs halved; 15. EDSS-associated costs from Martikainen and Sintonen13; 16 ¼ monitoring costs doubled;
17 ¼ monitoring costs halved; 18 ¼ relapse costs doubled; 19 ¼ relapse costs halved; 20 ¼ AE costs doubled; 21 ¼ AE costs halved; 22 ¼ societal approach14;
23 ¼ EDSS-associated quality of life (QoL) from Kobelt et al10; 24 ¼ similar QoL loss for all relapses; and 25 ¼ TEMSO30,32,33 patient characteristics and placebo
transition probabilities for RRMS EDSS.
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E. Soini et al.(whereas typically EDSS is assessed by a clinician); the
results in patients with RRMS and those with SPMS
were not separately reported; the reporting of DMT-
related costs in different EDSS classes was unclear;
and the adjusted cost (and relapse disutility) results
may not have been adequately captured owing to
statistical limitations (eg, costs should be assessed with
methods that account for both distribution skewness
and smearing).47,84 Finally, dividing the cost level
effect ofZ1 relapse by the mean number of relapses14
is potentially an inappropriate statistical approach.
Instead, the use of, for example, multilevel/hurdle
regression or simple semilog regression with relapses
as a continuous variable would have produced more
reliable results.
Based on the ﬁndings from the extensive sensitivity
analyses, the modeled base case results were nonethe-
less generally robust and generalizable, even when
based on the TEMSO trial setting or RRMS transi-
tions from British Columbia, Canada. Because of the
potential impact of inherent methodologic issues in
the DEFENSE survey,14 results based on an earlier
cost study13 were used in a sensitivity analysis and
demonstrated that the base case analysis was unlikely
to overestimate cost differences. The ranking of DMTs
in terms of primary outcome appeared to be robust to
sensible changes in the input variables.
Based on the trial evidence, the modeled results of
this study are valid. Teriﬂunomide 14 mg once daily
was the only ﬁrst-line DMT, injectable or oral, to show
a signiﬁcant reduction in both ARR and 3-month risk
for disability progression compared with placebo in 2
pivotal clinical trials.32,34 Compared with placebo,
teriﬂunomide signiﬁcantly reduced the rate of relapses
with neurologic sequelae, relapses leading to hospital-
ization, and relapses requiring intravenous corticoste-
roids, and teriﬂunomide-treated patients spent fewer
nights in hospital for relapse.32,35 Teriﬂunomide 14 mg
was associated with a signiﬁcant decrease in the annual
rate of all hospitalizations and emergency visits.33 In
addition, teriﬂunomide has a consistent tolerability
proﬁle, and AEs reported in patients receiving
teriﬂunomide in clinical trials were largely mild to
moderate (diarrhea, nausea, and hair thinning being
most common) and infrequently led to treatment
discontinuation. Patients reported improved treatment
satisfaction with teriﬂunomide compared with IFN-β1a
44 μg.37 Findings from a pooled analysis of data from
teriﬂunomide trials supported the earlier trial ﬁndings.92March 2017Alanine aminotransferase and blood pressure should be
monitored regularly, and complete blood cell counts
should be performed based on signs and symptoms (eg,
infections) during teriﬂunomide treatment (European
Medicines Agency. Teriﬂunomide [summary of product
characteristics] 2013).
Recently, Teri-PRO (Teriﬂunomide Patient-Reported
Outcomes Study), an international Phase IV real-world
study that measured patient-reported outcomes after the
initiation of teriﬂunomide treatment, demonstrated
a signiﬁcant increase in treatment satisfaction in patients
who were switched to teriﬂunomide from other
DMTs.93–95 In that study, a low rate of treatment
discontinuation (21.4%) was observed over a 48-week
period,93 which is consistent with the ﬁndings from the
present modeling study, with those from teriﬂunomide
clinical trials, and with those from other recent real-
world studies.96–102 In Teri-PRO, statistically signiﬁcant
improvements were also seen in QoL (as measured by
the MS International QoL scale), particularly on the
subscales of activities of daily living, psychological well-
being, symptoms, and coping.94
In addition, teriﬂunomide seems to have some
beneﬁt in patients who are switched from natalizumab
due to a risk for progressive multifocal leukoencephal-
opathy.101,102 However, it is important to note that
the risk for progressive multifocal leukoencephalop-
athy, a severe AE that is included in the DMF labeling
in Europe103 and the United States,104 was not
included in the present modeling study.
On the other hand, injection-site or skin reactions,
inﬂuenza-like symptoms, and neutralizing antibodies
are common AEs associated with injectable DMTs
and are among the most common reasons for dis-
continuing injectable DMTs.105,106 Flushing, hot
ﬂushes, and upper gastrointestinal symptoms are the
AEs most commonly reported with DMF therapy,
according to an assessment by the National Institute
for Health and Care Excellence.75 Based on real-world
evidence, AEs relating to DMF therapy can more
frequently result in treatment discontinuation in
comparison with teriﬂunomide96,97—an observation
not accounted for in the present study; in fact, the
modeling assumed a lesser withdrawal rate in DMF
users compared with teriﬂunomide users.
Among earlier cost-effectiveness studies of ﬁrst-line
MS DMTs,87–91,107–111 only 1 includes oral DMTs
(DMF, teriﬂunomide, US setting).111 In the present
modeling study, teriﬂunomide 14 mg and DMF 240549
Clinical Therapeuticsmg were cost-effective treatments versus BSC at the
WTP threshold values of €37,000 or €55,000/
QALY gained. However, at the most plausible
WTP of €25,000/QALY gained versus BSC, only
teriﬂunomide 14 mg was cost-effective. Further-
more, DMF 240 mg was not cost-effective versus
teriﬂunomide 14 mg at Finland’s unofﬁcial WTP
threshold values.
Overall health care efﬁciency, low drug prices, and
costly health care resources may be reasons behind the
results from the present analysis. However, the health
care setting in Finland can be regarded as a robust
default setting and as a benchmark for health eco-
nomic assessments for many reasons. Most important,
the productivity and efﬁciency of the Nordic health
care systems are high, as demonstrated in multiple
studies of the health care system in Finland.112–114
Social security code and national registries cover all
citizens in Finland, and one of the most advanced
biobank laws is in use for the willing. Furthermore,
Finland has a low pharmacy purchase price for
reimbursed drugs44 among European countries, and
tendering or patient access schemes have not been
possible for reimbursed drugs,115 eliminating
uncertainties about drug prices in Finland. Finland
also has national lists for health care unit costs68,69
and ofﬁcial indexes based on national statistics.71,85 In
some countries, such information does not exist.
Currently, Finland is undergoing health care, social
welfare, and regional government reform,116 which is
likely to result in digitized service solutions for the
primary (eg, benchmarking service producers) and
secondary (eg, market access to new drugs and
devices) uses of national, areal, local, and biobank
health care and social welfare data in terms of
effectiveness and cost-effectiveness.117 Furthermore,
the Finnish parliament recently received a proposal
for a risk-sharing scheme centered around an
agreement-based conditional reimbursement from the
government of Finland. However, the ofﬁcial whole-
sale price in the application would still need to be
affordable, and the risk-sharing scheme would be
available only through the optional application proc-
ess.118,119 This development has the potential to
further increase the efﬁciency of Finland’s health care
system and the relevance of modeling-based health
economic assessments. Finally, Finland’s guidance for
health economic analyses39 is well in line with many
other cost-effectiveness analysis guidelines.43,120–128550Health economic modeling is needed to handle the
multidimensional assessment challenge, to summarize
the trial evidence and local input data, to enable
extrapolations and discounting, and to produce results
in terms of generalizable outcomes with standard
interpretation. In the future, it will be necessary to
assess the effects of the risk-sharing scheme with some
treatments. Thus, by necessity, health economic mod-
els are simpliﬁcations of a very complicated reality.
Here, these assumptions are discussed.
In the model, potential treatment sequences were
excluded, and switching between different DMTs was
not accounted for. However, dropping out of ﬁrst-line
DMT altogether was included. To analyze the cost-
utility of ﬁrst-line RRMS DMTs, a sequential ap-
proach was not needed. A sequential approach would
be more viable in later treatment line assessment or in
health technology assessment searching for the opti-
mal treatment sequence. Furthermore, there was no
gold standard treatment sequence based on Finnish
data, and the treatment of patients with RRMS
seemed to be guided by per-patient decisions (which
are probably affected by disease severity, disease
progression, patient/clinician preferences, and poten-
tial DMT-related AEs).
In the selected modeling approach, all DMTs
compared were handled equally by assuming similar
treatment after the ﬁrst-line DMT, and the result was
not jeopardized by inherent and potentially problem-
atic assumptions related to second- and later-line
DMT efﬁcacy, tolerability, and washout. Further-
more, in a sequential model, the result may be
confounded by potential population changes between
the treatment lines. In the present analysis, the results
were directly related to differences due to the ﬁrst-line
DMT. In the evaluation, the ﬁrst-line DMTs were
being compared against each other, which potentially
was associated with less uncertainty and fewer as-
sumptions, and also in reduced bias and confounding
in comparison with a sequential approach relying on
multiple additional assumptions due to lack of data.
Furthermore, all of the DMTs in the comparison were
pharmacy prescription drugs, which overcomes issues
of comparing intravenously administered hospital
drugs (eg, further-line or high-activity MS treatments)
and pharmacy prescription drugs44,47 and are cur-
rently subject to public reimbursement in Finland.
In earlier cost-effectiveness analyses of treatments
for diseases other than MS, if the treatment sequenceVolume 39 Number 3
E. Soini et al.included treatment options that were not the most
cost-effective, the incremental cost-effectiveness of the
sequence deteriorated in comparison with base treat-
ments.45,48,129,130 First-line MS DMTs lacked pub-
lished cost-utility evidence; thus, there are no
supporting publications to benchmark or determine
the optimal MS treatment sequence. Furthermore, in
these situations, it was more important to know how
DMTs perform in comparison with the minimum case
(BSC). Based on the Finnish MS research registry data,
only a percentage of patients with RRMS are currently
actively treated. This may be for reasons connected
with efﬁcacy, tolerability, the patient, or the clinician.
Based on the Finnish MS research registry data, MS
DMT-related AEs seem to accumulate in some pa-
tients. However, owing to the similarity of some AEs
produced by frequently used ﬁrst-line MS injectable
DMTs, it is uncertain whether AEs occur in some
patients after changing from one ﬁrst-line DMT to
another. Furthermore, no well-controlled research
evidence exists demonstrating the clinical gains or
beneﬁts of switching the ﬁrst-line DMT.
EDSS transitions in this modeled evaluation were
based on data from Finland (RRMS) and London,
Ontario, Canada (SPMS),59 because these were most
comprehensive for the setting and because they
included survival data and were recorded and
checked by clinical experts. Other examples of
EDSS data include the British Columbia
database,57,58,131,132 the Lyon MS Cohort,133 the
Rennes MS Database,134 and the Sonya Slifka
Longitudinal MS Study.135 The effects of RRMS
EDSS transitions were tested in sensitivity analyses,
and the relative results remained unchanged. In fact,
the recently published RRMS transitions from British
Columbia, Canada57 agree with those from Finland.
Last, in addition to clinical real-world evidence,
future real-world studies should collect real-world
data to support modeled economic evaluations. They
should, accordingly, include comprehensive assess-
ments of the EDSS speciﬁed separately for RRMS;
SPMS and primary progressive MS; relapses; AEs and
withdrawals; comorbidities; patient income; and the
impact of these outcomes on resource use, costs, QoL,
and mortality. This real-world evidence may be
obtainable using structural treatment-monitoring sys-
tems and long-term registry data with sufﬁcient data
coverage and could enable the use of event-based or
microsimulation methods in the assessments. InMarch 2017addition, IIA type analysis should be used to increase
the clinical appeal of complex analyses.CONCLUSIONS
Data presented from the present modeling study
highlight the cost-effectiveness of teriﬂunomide 14
mg once daily compared with DMF 240 mg BID
when the commonly cited threshold values are taken
into account. In the present modeling study, teriﬂu-
nomide 14 mg also dominated all other commonly
used ﬁrst-line DMTs for RRMS in Finland and was
associated with the highest II.ACKNOWLEDGMENTS
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Clinical TherapeuticsSUPPLEMENTARY MATERIAL
Supplement A. EDSS-based RRMS and SPMS
transition matrices
EDSS1 is the key outcome in the assessment of MS
disability progression. In the Finnish Pirkanmaa-
Seinäjoki-Vaasa MS registry, there were 1359 patients
with MS with EDSS assessment data available, with
altogether 2458 measurements. These patients were
identiﬁed from administrative registries. The data
collection, case ascertainment procedure, and ethical
permits have been described in detail elsewhere.2,3
Incident MS cases diagnosed in the study region that
fulﬁlled the McDonald4 criteria were included. The
classiﬁcation of disease course to RRMS was
performed using standardized deﬁnitions.5
A total of 1242 patients had RRMS, and these
patients with RRMS had altogether 2299 EDSS
measurements between August 27, 1986, and Decem-
ber 31, 2010. Women accounted for 69.8% of the
patients. In all, 62.2% of the EDSS assessments were
carried out at the beginning of a DMT episode with an
EDSS score of 0–7. In 2010, EDSS values were0
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557.e1assessed for all patients alive (July 1, 2010, assumed,
if no speciﬁc day shown in the data).
EDSS Transitions in RRMS
Figure A.1 shows all EDSS measurements over time
for descriptive purposes. As can be seen, most EDSS
measurements were performed for patients with
RRMS (green colored dots). The ﬁgure also shows
that there was censoring in the EDSS measurements in
EDSS classes 6.5–9.5.
For descriptive purposes, combined Figure A.2
shows the development from one EDSS measurement
to the next among patients with RRMS, conditional
on particular EDSS scores.
EDSS development over time needs to be modeled
in order to estimate the progression of MS. MS
progression for the model was estimated using integer
RRMS EDSS scores (halves rounded up; 9.5 assumed
to be 9.0 because the patient is alive when EDSS is
9.5). The JAGS software V3.3.0,6 which is a statistical
program capable of analyzing Bayesian hierarchical
models by Markov Chain Monte Carlo (MCMC)2005 2010
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Figure A.2. EDSS development in RRMS population over time showing next EDSS scores. The blue line gives
the average expected EDSS over time and the shaded area is the 95% CI obtained by unadjusted
local polynomial smoothing of the raw data. CI ¼ confidence interval; EDSS ¼ Expanded
Disability Status Scale; RRMS ¼ relapsing-remitting multiple sclerosis.
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Table A.I. Annual transition probability matrix by EDSS for patients with RRMS based on the Finnish data.
From/To
RRMS
EDSS 0
RRMS
EDSS 1
RRMS
EDSS 2
RRMS
EDSS 3
RRMS
EDSS 4
RRMS
EDSS 5
RRMS
EDSS 6
RRMS
EDSS 7
RRMS
EDSS 8
RRMS
EDSS 9
RRMS
EDSS 10
RRMS
EDSS 0
0.67822 0.26314 0.04275 0.01136 0.00364 0.00077 0.00003 0.00003 0.00003 0.00003 0.00000
RRMS
EDSS 1
0.11299 0.60711 0.17922 0.06484 0.02725 0.00711 0.00037 0.00037 0.00037 0.00037 0.00000
RRMS
EDSS 2
0.01770 0.17312 0.37521 0.22712 0.14263 0.04960 0.00365 0.00365 0.00365 0.00365 0.00001
RRMS
EDSS 3
0.00547 0.07282 0.26542 0.25690 0.24007 0.11065 0.01216 0.01216 0.01216 0.01216 0.00002
RRMS
EDSS 4
0.00155 0.02710 0.14772 0.21289 0.30097 0.18210 0.03189 0.03189 0.03189 0.03189 0.00009
RRMS
EDSS 5
0.00045 0.00981 0.07124 0.13607 0.25204 0.20969 0.08010 0.08010 0.08010 0.08010 0.00031
RRMS
EDSS 6
0.00001 0.00027 0.00276 0.00786 0.02314 0.04173 0.23071 0.23071 0.23071 0.23071 0.00141
RRMS
EDSS 7
0.00001 0.00027 0.00276 0.00786 0.02314 0.04173 0.23071 0.23071 0.23071 0.23071 0.00141
RRMS
EDSS 8
0.00001 0.00027 0.00276 0.00786 0.02314 0.04173 0.23071 0.23071 0.23071 0.23071 0.00141
RRMS
EDSS 9
0.00001 0.00027 0.00276 0.00786 0.02314 0.04173 0.23071 0.23071 0.23071 0.23071 0.00141
RRMS
EDSS 10
0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 1.00000
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Table A.II. Annual probabilities of conversion to SPMS from RRMS by EDSS score.
EDSS score Calculation Hazard rate of conversion Calculation Probability
1 ln(2)/15 0.046210 1-exp(-0.046210) 0.045158
2 0.04621*e (̂0.25270*2) 0.076600 1-exp(-0.076600) 0.073739
3 0.04621*e (̂0.25270*3) 0.098622 1-exp(-0.098622) 0.093915
4 0.04621*e (̂0.25270*4) 0.126975 1-exp(-0.126975) 0.119245
5 0.04621*e (̂0.25270*5) 0.163480 1-exp(-0.163480) 0.150817
6 0.04621*e (̂0.25270*6) 0.210480 1-exp(-0.210480) 0.189805
7 0.04621*e (̂0.25270*7) 0.270993 1-exp(-0.270993) 0.237378
8 0.04621*e (̂0.25270*8) 0.348902 1-exp(-0.348902) 0.294538
9† 1.000000
10 0.000000
†Information for EDSS 9 was not available from the London Ontario dataset. Thus, a 100% conversion rate for patients with
RRMS in EDSS 9 was assumed.
E. Soini et al.simulation methods, was used to estimate the EDSS
transition probabilities.
When estimating the RRMS EDSS 0–9 transitions,
uniform priors were assumed because no earlier
Finnish transition probabilities data were available.
Based on a prior knowledge of the data in question,
60% of the mortality was assumed to be MS-related.7
This estimate was conservative in comparison to other
estimates, which have a higher proportion of MS-
related mortality (eg, 78.3% in Goodin et al8). The
results shown in Table A.I are well in line with the
recent British Columbia results.9
RRMS to SPMS Transition
The hazard rate (HR, λ) for conversion from
RRMS EDSS 1 to SPMS was calculated assuming an
exponential survival function (ie, a constant hazard of
converting to SPMS over time):
SðtÞ¼expðλtÞ
λ for an exponential distribution could be estimated
from the median time of conversion to SPMS, re-
ported to be 15 years based on London Ontario
data,10,13 ie:
λ¼ lnð2Þ=15
This gives an annual HR of 0.0462 for SPMS-
conversion of patients in EDSS 1.
The Finnish dataset includes only a few observa-
tions of conversion to SPMS, and an EDSS-speciﬁcMarch 2017rate could not be estimated from these. Based on the
London Ontario data, the Cox proportional hazards
model was:
HðtÞ¼HðtÞEDSS1:expðβXÞ
where H(t) is the HR of conversion for any EDSS
state; H(t)EDDS1, the HR of conversion for EDDS 1;
and β, the coefﬁcient (0.25270) of the relationship
between EDSS and the HR of progression between the
base case EDSS 1 and all other EDSS states.10,13 Using
Bender et al,11 the relationship was reformulated as:
ln
HðtÞ
HðtÞEDSS1
 
¼β:X
Thus:
HðtÞ¼λ:eβ:X
This was used to derive the HR of conversion from
EDSS 1 through each successive stage to EDSS 8
(Table A.II). All estimated HRs were then
subsequently converted into probabilities12:
p¼1expðrtÞEDSS Transitions in SPMS
For SPMS transitions, data from the London
Ontario MS registry10,13 were available and used
(Table A.III), because the Finnish register data had
too few EDSS measurements for patients with SPMS.557.e4
Table A.III. Annual transition probability matrix by EDSS for patients with SPMS based on London Ontario data.10,13
From/To
SPMS
EDSS 0
SPMS
EDSS 1
SPMS
EDSS 2
SPMS
EDSS 3
SPMS
EDSS 4
SPMS
EDSS 5
SPMS
EDSS 6
SPMS
EDSS 7
SPMS
EDSS 8
SPMS
EDSS 9
SPMS
EDSS 10
SPMS
EDSS 0
1.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
SPMS
EDSS 1
0.000 1.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
SPMS
EDSS 2
0.000 0.000 0.455 0.375 0.099 0.041 0.027 0.002 0.001 0.000 0.000
SPMS
EDSS 3
0.000 0.000 0.000 0.563 0.280 0.088 0.061 0.005 0.002 0.000 0.000
SPMS
EDSS 4
0.000 0.000 0.000 0.000 0.482 0.281 0.218 0.013 0.006 0.000 0.000
SPMS
EDSS 5
0.000 0.000 0.000 0.000 0.000 0.340 0.597 0.041 0.023 0.000 0.000
SPMS
EDSS 6
0.000 0.000 0.000 0.000 0.000 0.000 0.870 0.081 0.048 0.000 0.000
SPMS
EDSS 7
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.645 0.349 0.006 0.000
SPMS
EDSS 8
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.992 0.008 0.000
SPMS
EDSS 9
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.000 0.000
SPMS
EDSS 10
0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.000
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TREATMENT COSTS, AND DISUTILITIES
Risks of AEs
Adverse events (AEs) were included to the modeling
based on aZ4% difference between active treatment and
placebo and/or clear inclusion in a previous NICE HTA
submission (Table B.I). Nearly all AEs related to DMF,
GA, interferons, and teriﬂunomide are mild to moderate
and of short duration. The reason for not including the
AEs with a o4% difference between placebo and active
treatment and no NICE HTA reference was to simplify
the analysis. Recently, the FDA added a progressive
multifocal leukoencephalopathy (PML, a very severe
AE) scenario to the DMF label. However, possible
PML risk with DMF was ignored owing to uncertainty
related to exact PML risk (usually PML risk accumulates
over time).
In order to convert risk of AEs from studies to
annualized risk of AEs, the risk of AEs was converted
to a rate using a standard formula,1 and the resulting
annualized AE rates were then converted back to
annualized probabilities/risks (Table B.I).
AEs were assumed to occur at most once per cycle.
However, injection-site reaction, fever, and nausea
tend to occur after every interferon dose, and chest
pain, palpitation, and dyspnea may happen after every
GA dose for subjects who have a particular AE.
Consequently, the impact of those AEs may be under-
estimated for interferons and GA.
Treatment of AEs
In Finnish practice, the active treatment of severe AEs
takes place in the neurology unit, and moderate AEs
result in phone calls to the neurologic department. More
severe AEs, including injection-site reactions, chest pain,
palpitation, dyspnea, hot ﬂush, and vomiting, require
specialist consultation (Table B.II). Chest pain and
ﬂushing, palpitation, and dyspnea related to GA are
usually transient.8 Asthenia, chills, diarrhea, ﬂush, hair
thinning, and nausea alone do not usually need active
treatment; thus, phone contact to the neurologic
department was assumed for these. Conservatively,557.e6
Table B.I. Annualized risk of AEs associated with treatment.
Treatment Adverse event (AE) Annualized probability Rate source
DMF 240 mg
(Tecﬁderas)
Flushing 19.0% Aggregate weighted estimate
based on the trials referred to
in the HTA submission (NICE)2
Nausea 6.2%
Upper abdominal pain 5.1%
Vomiting 4.3%
Hot ﬂush 3.4%
GA 20 mg
(Copaxones)
Injection-site reaction 68.4% Johnson et al3
Dyspnea 6.6%
Chest pain, ﬂushing 2.8%
Palpitation 2.4%
IFNβ-1a-SC 44 mg
(Rebifs)
Injection-site reaction 38.3% PRISMS Study Group4
Myalgia 7.0%
Neutralizing antibodies 6.5%
Fever 6.1%
IFNβ-1a-IM 30 mg
(Avonexs)
Headache 42.6% Jacobs et al5
Inﬂuenza-like
symptoms
37.4%
Muscle pain 18.5%
Nausea 16.9%
Neutralizing antibodies 14.0% year 1, 8.0% year 2þ
Fever 12.5%
Asthenia 11.1%
Chills 11.1%
Diarrhea 8.3%
IFNβ-1b 250 mg
(Betaferons)
Injection-site reaction 80.0% year 1, 44.0% year 2þ IFNB Multiple Sclerosis Study
Group6Neutralizing antibodies 27.4% year 1, 5.6% year 2þ
Inﬂuenza-like
symptoms
8.0% year 1, 5.5% year 2þ
Teriﬂunomide 14 mg
(Aubagios)
Diarrhea 9.1% O’Connor et al7
Nausea 6.9%
Hair thinning 6.6%
Clinical Therapeuticsnone of the AEs included were assumed to result in
hospitalization.
Ibuprofen is used to treat fever, headache, inﬂu-
enza, muscle pain, and myalgia. Antihistamine is used
to treat (at minimum) the hot ﬂush associated with
DMF. No other drugs were assumed to be used for the
treatment of DMT-related AEs.
QoL Loss of AEs
Resource use and costs associated with AE manage-
ment are given in Table B.II, and QoL losses and
durations associated with AEs are given in Table B.III.557.e7REFERENCES1. Fleurence RL, Hollenbeak CS. Rates and proba-
bilities in economic modelling: transformation,
translation and appropriate application. Pharma-
coEconomics. 2007;25:3-6.2. National Institute for Health and Care Excellence.
Dimethyl fumarate for treating relapsing-
remitting multiple sclerosis. NICE technology
appraisal guidance 320. London: National Insti-
tute for Health and Care Excellence; 2014.3. Johnson KP, Brooks BR, Cohen JA, et al. Copoly-
mer 1 reduces relapse rate and improves disabilityVolume 39 Number 3
Table B.II. Resource use and costs (h) associated with AE management.
Adverse event (AE) Cost (h) Resources (original unit cost and source)
Asthenia, chills, diarrhea, ﬂush, hair
thinning, or nausea
24.43 Phone call (€24.439 at 2014 values10)
Upper abdominal pain 30.73 Phone call (€24.439 at 2014 values10) þ blood test
taking (€5.4711 at 2014 values10) þ LFT (€1.0012)
Fever, headache, inﬂuenza symptoms,
muscle pain, or myalgia
35.18 Phone call (€24.439 at 2014 values10) þ NSAID
(ibuprofen 600mg €10.7413)
Chest pain, ﬂushing, dyspnea,
injection-site reaction, palpitation,
or vomiting
340.76 Specialist visit (€340.76 incl. 5% copayment9 at 2014
values10)
Hot ﬂush 358.12 Specialist visit (€340.76 incl. 5% copayment9 at 2014
values10) þ antihistamine (desloratadine 5 mg
€17.3613)
Neutralizing antibodies 438.74 Specialist visit (€340.76 incl. 5% co-payment9 at 2014
values10) þ blood test taking (€5.4711 at 2014
values10) þ antibody test (€92.5014)
Table B.III. Quality of life (QoL) loss and its duration associated with AEs.
Adverse event (AE) QoL loss Duration Assumption Disutility source
Flushing, hair thinning, neutralizing antibodies,
or upper abdominal pain
0.0001 1 year* Assumption –
Headache 0.0827 2 days* – Soini and Hallinen15
Injection-site reaction 24 hours* Headache
Muscle pain or myalgia 1 week*
Diarrhea 0.1034 2.5 days16 –
Asthenia or chills 1 week* Diarrhea
Fever 24 hours*
Inﬂuenza-like symptoms 1 week17
Vomiting 3 weeks*
Nausea 1 week* –
Chest pain, ﬂushing, dyspnea, or palpitation 0.1244 24 hours8 Somnolence
Hot ﬂush 3 weeks*
*Expert opinion.
E. Soini et al.
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e17030.SUPPLEMENT C. PROBABILISTIC SENSITIVITY
ANALYSIS RESULTS
Probabilistic Results
Table C.I reports the 15-year mean and 2.5%–
97.5% percentile results based on 2000 simulations.Cost-Effectiveness Plane
Figure C.1 shows the joint distributions of 15-year
cost-and-effect differences (increments) for the non-
dominated teriﬂunomide (teriﬂunomide is in the origin
of Figure C.1) vs other DMTs.Cost-Effectiveness Acceptability Frontier
Figure C.2 depicts the cost-effectiveness accept-
ability frontier (CEAF). Based on the CEAF, teriﬂu-
nomide had more than 50% cost-effectiveness
probabilities with ICERs less than 77,416 vs other
ﬁrst-line DMTs for RRMS (Figure C.2).Bayesian Treatment Ranking
According to Bayesian treatment ranking, teriﬂu-
nomide was the best option, with a willingness-to-pay
threshold of €0 (99.9%), €25,000 (100.0%), €37,000
(100.0%), €55,000 (96.2%), and €68,000 (75.2%)
per QALY gained.Volume 39 Number 3
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Figure C.1. Probabilistic incremental cost and QALY
results in a cost-effectiveness plane for
teriflunomide vs other first-line treat-
ments (2000 simulations). DMF ¼
dimethyl fumarate; GA ¼ glatiramer
acetate; IFNβ-1a-SC ¼ interferon
beta-1a-subcutaneous; IFNβ-1a-IM
¼ interferon beta-1a-intramuscular;
IFNβ-1b-SC ¼ interferon beta-1b-
subcutaneous; QALY ¼ quality-ad-
justed life-year.
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Figure C.2. Cost-effectiveness acceptability frontier
for first-line treatments. DMF ¼
dimethyl fumarate; QALY ¼ qual-
ity-adjusted life-year.
Table C.I. Probabilistic results.
Treatment Mean QALYs 2.5% 97.5% Mean costs (h) 2.5% 97.5%
DMF 7.335 6.847 7.781 376,159 335,827 420,955
Teriﬂunomide 7.242 6.741 7.683 369,045 327,547 415,265
IFNβ-1a-SC 44mg 7.112 6.612 7.556 373,417 329,267 419,587
GA 6.990 6.445 7.457 393,558 352,185 440,894
IFNβ-1a-IM 30mg 6.971 6.415 7.444 387,785 344,135 436,228
IFNβ-1b-SC 250mg 6.575 6.003 7.095 428,286 380,681 482,486
DMF ¼ dimethyl fumarate; GA ¼ glatiramer acetate; IFNβ-1a-SC ¼ interferon beta-1a-subcutaneous; IFNβ-1a-IM ¼
interferon beta-1a-intramuscular; IFNβ-1b-SC ¼ interferon beta-1b-subcutaneous; QALY ¼ quality-adjusted life-year.
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